1,094 results on '"Massie, Allan B."'
Search Results
52. 413.5: HCV-Viremic Donor Allograft Consideration by Organ Type And Year, Among Adult and Pediatric Solid Organ Transplant Candidates
53. 400.5: Outcomes After Declining a Donation After Cardiac Death (DCD) Liver for Transplant Candidates in the United States
54. 331.5: Transplant Candidate Outcomes After Accepting Sclerotic Kidneys in the United States, 2015-2018
55. 330.4: SARS-coV-2 Antibody Response to a Third Dose of Homologous mRNA Vaccination in Liver Transplant Recipients
56. 314.1: Response to a Pandemic: The Fall and Rise of Kidney Transplantation in the United States
57. 313.13: Quantification of Center Aggressiveness in Accepting Suboptimal Kidney Donations From Deceased Donors in the US
58. 249.8: SARS-coV-2 Antibody Response by mRNA Vaccine Platform in Incrementally Immunosuppressed Patients
59. 230.3: Antibody Response to a Third Dose of SARS-CoV-2 Vaccine in Heart and Lung Transplant Recipients
60. 230.6: Ad.26.COV2.S Versus BNT162b2 or mRNA-1273 as a Third Dose in Solid Organ Transplant Recipients Seronegative After 2-dose mRNA Vaccination
61. 230.1: Incidence and Severity of COVID-19 Infections Among Triple-vaccinated Solid Organ Transplant Recipients During the Omicron Variant Surge in the United States (12/25/2021-3/1/2022)
62. 210.5: Differential Immunogenicity of mRNA-1273 Versus BNT162b2 as a Third Vaccine Dose for Solid Organ Transplant Recipients Seronegative After Two BNT162b2 Doses.
63. Incidence and Severity of COVID-19 Among Vaccinated Solid Organ Transplant Recipients During the Omicron Wave
64. Effect of Mycophenolate Mofetil Dosing on Antibody Response to SARS-CoV-2 Vaccination in Heart and Lung Transplant Recipients
65. 6-mo Antibody Kinetics and Durability After 3 Doses of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
66. Identifying scenarios of benefit or harm from kidney transplantation during the COVID-19 pandemic: A stochastic simulation and machine learning study
67. Effects of COVID-19 pandemic on pediatric kidney transplant in the United States
68. How do highly sensitized patients get kidney transplants in the United States? Trends over the last decade
69. Early impact of COVID-19 on transplant center practices and policies in the United States
70. Short Report: Evaluating the Effects of Automated Donor Referral Technology on Deceased Donor Referrals
71. Letter to the editor: Poor sensitivity of anti‐nucleocapsid antibody in detecting prior COVID‐19 in vaccinated solid organ transplant recipients
72. A2/A2B to B deceased donor kidney transplantation in the Kidney Allocation System era
73. National Attitudes Towards Living Kidney Donation in the United States: Results of a Public Opinion Survey
74. Thirty-Year Trends in Perioperative Mortality Risk for Living Kidney Donors.
75. Development of a Patient Reported Measure of Experimental Transplants with HIV and Ethics in the United States (PROMETHEUS)
76. Panel-reactive Antibody and the Association of Early Steroid Withdrawal With Kidney Transplant Outcomes
77. Temporal Trends in Utilization and Outcomes of DCD Livers in the United States
78. Pediatric deceased donor kidney transplant outcomes under the Kidney Allocation System
79. A donor risk index for graft loss in pediatric living donor kidney transplantation
80. Obesity and long-term mortality risk among living kidney donors
81. The landscape of international living kidney donation in the United States
82. Antibody Response to an mRNA SARS-CoV-2 Vaccine Following Initial Vaccination With Ad.26.COV2.S in Solid Organ Transplant Recipients: A Case Series
83. Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics
84. Six-month Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients
85. Induction immunosuppression agents as risk factors for incident cardiovascular events and mortality after kidney transplantation
86. The national landscape of deceased donor kidney transplantation for the highly sensitized: Transplant rates, waitlist mortality, and posttransplant survival under KAS
87. Who can tolerate a marginal kidney? Predicting survival after deceased donor kidney transplant by donor–recipient combination
88. Antibody Response to a Fourth Dose of a SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
89. Safety and Reactogenicity of 2 Doses of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients
90. Antibody Kinetics and Durability in SARS-CoV-2 mRNA Vaccinated Solid Organ Transplant Recipients
91. Trends in Heart and Lung Transplantation in the United States Across the COVID-19 Pandemic
92. COVID-19 and Access to Kidney Transplantation for Older Candidates in the United States: A National Registry Study
93. External Validation of Toulouse-Rangueil eGFR12 Prediction Model After Living Donor Nephrectomy
94. Characterizing the risk of human leukocyte antigen-incompatible living donor kidney transplantation in older recipients
95. To decline or not to decline: Consequences of decision-making regarding lung offers from donors with hepatitis C
96. Better Understanding the Disparity Associated With Black Race in Heart Transplant Outcomes: A National Registry Analysis
97. Mitigating the Disparate Impacts of Longevity Matching of Kidney Transplants
98. Kidney Transplantation Confers Survival Benefit for Candidates With Pulmonary Hypertension
99. Living donor postnephrectomy kidney function and recipient graft loss: A dose-response relationship
100. Kidney offer acceptance at programs undergoing a Systems Improvement Agreement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.